Cost-effectiveness of a carcinoembryonic antigen (CEA) based follow-up programme for colorectal cancer (the CEA Watch trial)

Colorectal Disease

Volumn 18, Issue 3, 2016, Pages O91-O96

  Verberne, C J ^a   Wiggers, T ^a   Grossmann, I ^a,b   de Bock, G H ^a   Vermeulen, K M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Colorectal cancer; Costs; Follow up

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ABSENTEEISM; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; COLORECTAL CANCER; COLORECTAL SURGERY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PATIENT SAFETY; PATIENT TRANSPORT; PRIORITY JOURNAL; QUESTIONNAIRE; ADULT; AMBULATORY CARE; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; EVALUATION STUDY; FEMALE; MALE; MIDDLE AGED; PROCEDURES; PROGRAM EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

ADULT; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; OFFICE VISITS; PROGRAM EVALUATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84962795040     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.13273     Document Type: Article

References (21)

1. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998; 41: 1127-33.
2. Rodriguez-Moranta F, Salo J, Arcusa A et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006; 24: 386-93.
3. Secco GB, Fardelli R, Gianquinto D et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002; 28: 418-23.
4. Primrose JN, Perera R, Gray A et al. FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311: 263-70.
5. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; 1: CD002200.
6. Baca B, Beart RW Jr, Etzioni DA. Surveillance after colorectal cancer resection: a systematic review. Dis Colon Rectum 2011; 54: 1036-48.
7. Verberne CJ, Zhan Z, van den Heuvel E et al. Carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging: results of the randomized 'CEA Watch' trial. Eur J Surg Oncol 2015; 41: 1188-96.
8. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-21.
9. Korner H, Soreide K, Stokkeland PJ, Soreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg 2005; 9: 320-8.
10. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998; 228: 59-63.
11. Zhan Z, van den Heuvel ER, Doornbos PM et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow-up study. J Clin Epidemiol 2014; 67: 454-61.
12. Hakkaart-van Roijen L, Tan S, Bouwmans C. Handleiding voor kostenonderzoek - methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Tijdschrift Voor Gezondheidswetenschappen 2012; 6: 367-72.
13. Sandler RS, Freund DA, Herbst CA Jr, Sandler DP. Cost effectiveness of postoperative carcinoembryonic antigen monitoring in colorectal cancer. Cancer 1984; 53: 193-8.
14. Staib L, Link KH, Beger HG. Follow-up in colorectal cancer: cost-effectiveness analysis of established and novel concepts. Langenbecks Arch Surg 2000; 385: 412-20.
15. Ketteniss M, Schutz G, Ulrich B. Costs and efficiency of a tumor follow-up program for the detection of colorectal liver metastases. Int J Colorectal Dis 2001; 16: 28-31.
16. van den Hout WB, van den Brink M, Stiggelbout AM, van de Velde CJ, Kievit J. Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer 2002; 38: 953-63.
17. National Institute for Health and Care Excellence (NICE). Process and methods guide - The guidelines manual. 2012. Available at http://www.nice.org.uk/article/pmg6/resources/non-guidance-the-guidelines-manual-pdf.
18. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 1997; 8: 1081-7.
19. Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 1990; 65: 2580-7.
20. Grossmann I, Verberne C, de Bock G et al. The role of high frequency dynamic threshold (HiDT) serum carcinoembryonic antigen (CEA) measurements in colorectal cancer surveillance: a (revisited) hypothesis paper. Cancer 2011; 3: 2302-15.
21. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-26.